US 12,343,434 B2
Hybrid membrane camouflaged nanomedicine loaded with oxidative phosphorylation inhibitor and preparing method thereof
Yan Zou, Henan (CN); Yajing Sun, Henan (CN); Bingyang Shi, Henan (CN); Meng Zheng, Henan (CN); and Mingcong Hao, Henan (CN)
Assigned to Henan University, Henan (CN)
Filed by Henan University, Henan (CN)
Filed on May 7, 2022, as Appl. No. 17/739,090.
Claims priority of application No. 202110555902.1 (CN), filed on May 19, 2021.
Prior Publication US 2022/0378712 A1, Dec. 1, 2022
Int. Cl. A61K 9/51 (2006.01); A61K 9/50 (2006.01); A61K 31/4184 (2006.01); A61P 35/00 (2006.01)
CPC A61K 9/5176 (2013.01) [A61K 9/5068 (2013.01); A61K 9/5073 (2013.01); A61K 9/5146 (2013.01); A61K 31/4184 (2013.01); A61P 35/00 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A mitochondria-cancer cell hybrid membrane camouflaged nanomedicine loaded with oxidative phosphorylation inhibitor, comprising an inner core and an outer shell,
wherein the outer shell is coated on a periphery of the inner core, wherein the inner core comprises a ROS-responsive drug-loading nanoparticle and a drug loaded by the ROS-responsive drug-loading nanoparticle, wherein the drug is the oxidative phosphorylation inhibitor, and wherein the outer shell is a hybrid membrane of a mitochondria membrane and a cancer cell membrane;
wherein the ROS-responsive drug-loading nanoparticle comprises polyethylene glycol-poly(β-butyrolactone) having a following structural formula:

OG Complex Work Unit Chemistry
wherein a polymerization degree x of poly(β-butyrolactone) in the polyethylene glycol-poly(β-butyrolactone) is 8-12.